Afinitor Disperz — CareFirst (Caremark)
endometrial carcinoma
Initial criteria
- Endometrial carcinoma: in combination with letrozole
- Uterine sarcoma: single agent for subsequent therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months